BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy FDA mulls compounding for peptides previously flagged over safety risks BioSpace Regulatory Updates on Compounded Peptides New Drug Loft and VLS Pharmacy